Stocklytics Platform
Asset logo for symbol LUNG
Pulmonx
LUNG56
$7.92arrow_drop_down0.62%-$0.05
Asset logo for symbol LUNG
LUNG56

$7.92

arrow_drop_down0.62%

Performance History

Chart placeholder
Key Stats
Open$7.97
Prev. Close$7.97
EPS-1.54
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range7.75
8.15
52 Week Range5.67
14.83
Ratios
EPS-1.54

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About Pulmonx (LUNG)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Glendon E. French
Headquarters
Redwood City
Employees
269
Exchange
NASDAQ
add Pulmonx to watchlist

Keep an eye on Pulmonx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Pulmonx (LUNG) stock price performance year to date (YTD)?

As of the latest data, Pulmonx (LUNG) has a year-to-date price change of -37.64%. Over the past month, the stock has experienced a price change of 36.08%. Over the last three months, the change has been 5.46%. Over the past six months, the figure is -39.12%.

help
What is Pulmonx's (LUNG) price per share?

The current price per share for Pulmonx (LUNG) is $7.92. The stock has seen a price change of -$0.05 recently, indicating a -0.63% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Pulmonx (LUNG)?

For Pulmonx (LUNG), the 52-week high is $14.84, which is 87.31% from the current price. The 52-week low is $5.67, the current price is 39.68% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Pulmonx (LUNG) a growth stock?

Pulmonx (LUNG) has shown an average price growth of 0.41% over the past three years. It has received a score of 9 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pulmonx as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
Is Pulmonx (LUNG) a profitable company?

Pulmonx (LUNG) has a net income of -$60.84M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.32% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -77.1% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $68.68M, with a revenue growth rate of 27.98%, providing insight into the company's sales performance and growth. The gross profit is $50.35M. Operating income is noted at -$61.94M. Furthermore, the EBITDA is -$58.54M.

help
What is the market capitalization of Pulmonx (LUNG)?

Pulmonx (LUNG) has a market capitalization of $313.63M. The average daily trading volume is 278.07K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level